- Stocks
- Pharma & Healthcare
- Natco Pharma
Natco Pharma share price
NSE: NATCOPHARMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Natco Pharma at a glance
Natco Pharma (NSE: NATCOPHARM) closed at ₹785.00 on 22 Oct 2026, up 0.13% on the day. With a market capitalisation of ₹14,063 Cr, it ranks 452nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 9.9× trailing earnings, against a return on equity of 15.4% in FY26. Over the past year the share price has fallen 3.3%. Its 52-week range is ₹773.60 (22 Oct 2026) to ₹1,226.80 (12 May 2026); the last close is 36.0% below the high. Promoters held 49.42% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14,063 CrRank 452 on NSE
- P/E (trailing)
- 9.9×
- Price to book
- 1.89×FY26
- ROE
- 15.4%FY26
- ROCE
- 16.3%FY26
- Debt to equity
- 0.08FY26
- Net profit margin
- 33.6%FY26
- Book value / share
- ₹515.15FY26
- 52-week high
- ₹1,226.8012 May 2026
- 52-week low
- ₹773.6022 Oct 2026
- 1-year return
- −3.3%
- RSI (14-day)
- 38.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.13% | +0.3% | −2.7% | −15.7% | −3.3% |
Natco Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,052 Cr | ₹1,945 Cr | ₹2,707 Cr | ₹3,999 Cr | ₹4,430 Cr | — |
| Operating profit | ₹580 Cr | ₹202 Cr | ₹862 Cr | ₹1,674 Cr | ₹2,291 Cr | — |
| Net profit | ₹442 Cr | ₹170 Cr | ₹715 Cr | ₹1,388 Cr | ₹1,883 Cr | — |
| EPS (₹) | ₹24.00 | ₹9.00 | ₹39.00 | ₹77.00 | ₹105.00 | — |
| Cash from operations | ₹299 Cr | ₹47 Cr | ₹849 Cr | ₹1,212 Cr | ₹1,697 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹100 Cr |
| Shareholders' equity | ₹4,122 Cr | ₹4,264 Cr | ₹4,874 Cr | ₹5,853 Cr | ₹7,607 Cr | ₹9,221 Cr |
Natco Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.56% | 49.56% | 49.48% | 49.48% | 49.42% | 49.42% |
| Foreign institutions | 17.49% | 15.51% | 14.09% | 15.16% | 17.37% | 16.99% |
| Domestic institutions | 5.65% | 5.82% | 5.87% | 5.39% | 5.46% | 5.62% |
| Non-institutions | 27.29% | 29.11% | 30.56% | 29.96% | 27.75% | 27.97% |
Natco Pharma vs peers
The listed Pharma & Healthcare companies nearest to Natco Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,848 Cr | 37.1 | 13.4% |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,686 Cr | 46.7 | 10.4% |
| VIJAYAVijaya Diagnostic Centre | ₹1,382.60 | +2.04% | +42.1% | ₹14,324 Cr | 82.5 | 18.1% |
| INDGNIndegene | ₹577.95 | −1.15% | +8.6% | ₹14,171 Cr | 34.8 | 12.8% |
| NATCOPHARMNatco Pharma | ₹785.00 | +0.13% | −3.3% | ₹14,063 Cr | 9.9 | 15.4% |
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,343 Cr | 32.1 | 13.8% |
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,294 Cr | 52.4 | — |
Ask anything about Natco Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against NATCOPHARM's own history. Try: “Why has NATCOPHARM moved over the last three months?” · “Backtest a 50-day moving-average crossover on NATCOPHARM over five years” · “Compare NATCOPHARM with JUBLPHARMA on margins and valuation”
Frequently asked questions about Natco Pharma
What is the share price of Natco Pharma today?
Natco Pharma (NSE: NATCOPHARM) last closed at ₹785.00 on 22 Oct 2026. Its 52-week high is ₹1,226.80 and its 52-week low is ₹773.60.
What is the market cap of Natco Pharma?
Natco Pharma's market capitalisation is ₹14,063 Cr (₹14,063 Cr) at the 22 Oct 2026 close, ranking 452nd among the NSE companies Pivot tracks.
What is the P/E ratio of Natco Pharma?
Natco Pharma trades at a trailing P/E of 9.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of Natco Pharma?
Return on equity was 15.4% in FY26 and return on capital employed was 16.3% in FY26 (consolidated figures).
Is Natco Pharma a debt-free company?
No. Natco Pharma's debt-to-equity ratio was 0.08 in FY26, with total debt of ₹100 Cr.
How has Natco Pharma stock performed over the last year?
Natco Pharma's share price has fallen 3.3% over the past year, −15.7% over three months and −2.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Natco Pharma?
As of 30 Jun 2026: promoters 49.42%, foreign institutions 16.99%, domestic institutions 5.62%, non-institutions 27.97%.
Who are Natco Pharma's competitors?
The listed Pharma & Healthcare companies closest to Natco Pharma by market cap are Jubilant Pharmova, Poly Medicure, Vijaya Diagnostic Centre, Indegene, Marksans Pharma and Concord Biotech.
Is Natco Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Natco Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NATCOPHARM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text